13.68

1.94% -0.27

Mediwound Ltd (MDWD)

Overview News Price History Option Chain Discussions Forecast Stock Split

Mediwound Ltd stock is traded at $13.68, with a volume of 32,777. It is down -1.94% in the last 24 hours and up +3.56% over the past month. MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Previous Close:

$13.95

Open:

$13.8

24h Volume:

32,777

Relative Volume:

0.37

Market Cap:

$176.74M

Revenue:

$14.48M

Net Income/Loss:

$-26.11M

P/E Ratio:

-6.0555

EPS:

-2.2591

Net Cash Flow:

$-23.86M

1W Performance:

+3.48%

1M Performance:

+3.56%

6M Performance:

-18.96%

1Y Performance:

-23.40%

1-Day Range:

$13.59

$13.80

1-Week Range:

$13.00

$13.99

52-Week Range:

$12.52

$20.03

Mediwound Ltd Stock (MDWD) Company Profile

Name

Mediwound Ltd

Sector

Healthcare (1074)

Industry

Biotechnology (597)

Phone

Address

Employee

121

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

MDWD's Discussions on Twitter

Compare MDWD vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDWD Mediwound Ltd	13.69	180.10M	14.48M	-26.11M	-23.86M	-2.2591
VRTX Vertex Pharmaceuticals Inc	510.97	130.53B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	791.62	82.77B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	185.19	72.88B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	944.68	60.30B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	362.74	41.64B	5.76B	514.49M	1.10B	4.4813

Mediwound Ltd Stock (MDWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
May-02-25	Initiated	Alliance Global Partners	Buy
Feb-28-25	Initiated	Craig Hallum	Buy
Jul-16-24	Reiterated	Maxim Group	Buy
Dec-22-22	Initiated	Maxim Group	Buy
Jul-18-22	Resumed	Oppenheimer	Outperform
Sep-23-20	Initiated	BTIG Research	Buy
Nov-28-16	Initiated	Aegis Capital	Buy
Aug-17-16	Initiated	Wells Fargo	Outperform
Apr-16-14	Initiated	Oppenheimer	Outperform

View All

Mediwound Ltd Stock (MDWD) Latest News

Sep 22, 2026

MediWound Ltd. Receives Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid - marketscreener.com

Sep 22, 2026

MediWound receives $3.3M from DoD for NexoBrid development By Investing.com - Investing.com Nigeria

Sep 22, 2026

A $21.8M program is developing burn care that can stay at room temperature - Stock Titan

Sep 22, 2026

Sep 17, 2026

TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Sep 17, 2026

Sep 14, 2026

Reviewers found no safety concerns in MediWound's wound trial. - Stock Titan

Sep 14, 2026

Sep 11, 2026

(MDWD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Sep 11, 2026

Sep 02, 2026

Director of MediWound (NASDAQ: MDWD) trades shares via spouse - Stock Titan

Sep 02, 2026

An FDA-approved burn treatment company’s CEO will join a New York fireside chat. - Stock Titan

Sep 02, 2026

Sep 01, 2026

Precision Trading with Mediwound Ltd. (MDWD) Risk Zones - Stock Traders Daily

Sep 01, 2026

Aug 28, 2026

Hungarian fund owns double-digit MediWound (MDWD) stake - Stock Titan

Aug 28, 2026

Aug 26, 2026

MediWound (NASDAQ: MDWD) seller Hess plans $50K, 3,958-share sale - Stock Titan

Aug 26, 2026

Aug 25, 2026

New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq - Benzinga

Aug 25, 2026

Aug 20, 2026

MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.ca

Aug 20, 2026

Aug 19, 2026

MediWound (MDWD) Q2 2026 Results: The Available Earnings Metric Delivers a Beat in the Current Update; Closing Reaction: The Stock Records a 1.87% Increase in the Current UpdateRevenue Per Share - vinanet.vn

Aug 19, 2026

Aug 18, 2026

MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayNegative Surprise Momentum - dars.gov.et

Aug 18, 2026

What is HC Wainwright's Forecast for MediWound Q3 Earnings? - MarketBeat

Aug 18, 2026

Aug 17, 2026

Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment - TradingView

Aug 17, 2026

MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus

Aug 17, 2026

Aug 16, 2026